Biocept Stock Forecast, Price & News

Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept or view top-rated stocks.

How has Biocept's stock been impacted by COVID-19?

Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BIOC shares have decreased by 15.1% and is now trading at $3.20.
View which stocks have been most impacted by COVID-19.

Are investors shorting Biocept?

Biocept saw a decrease in short interest in December. As of December 15th, there was short interest totaling 372,700 shares, a decrease of 29.1% from the November 30th total of 525,900 shares. Based on an average daily trading volume, of 264,900 shares, the days-to-cover ratio is presently 1.4 days.
View Biocept's Short Interest.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Biocept.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its earnings results on Monday, November, 15th. The medical research company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.06. The medical research company had revenue of $17.47 million for the quarter, compared to the consensus estimate of $16.87 million. Biocept had a net margin of 4.71% and a trailing twelve-month return on equity of 10.35%. During the same quarter last year, the firm posted ($0.43) earnings per share.
View Biocept's earnings history.

When did Biocept's stock split? How did Biocept's stock split work?

Shares of Biocept reverse split on the morning of Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

Who are Biocept's key executives?

Biocept's management team includes the following people:

• Michael W. Nall, President, Chief Executive Officer & Director
• Timothy C. Kennedy, CFO, Senior VP-Operations & Secretary
• Lyle J. Arnold, Chief Scientific Officer & Senior Vice President
• Michael C. Dugan, Chief Medical Officer & Medical Director
• Michael W. Brown, General Counsel, Compliance & Privacy Officer

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Biocept's key competitors?

Some companies that are related to Biocept include Sera Prognostics (SERA), Celcuity (CELC), Enzo Biochem (ENZ), Exagen (XGN), MDxHealth (MDXH), Psychemedics (PMD), OpGen (OPGN), Vyant Bio (VYNT), CannLabs (CANL), PharmChem (PCHM), AnPac Bio-Medical Science (ANPC), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), CBA Florida (CBAI) and Zicix (ZICX).
View all of BIOC's competitors.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $3.20.

How much money does Biocept make?

Biocept has a market capitalization of $53.89 million and generates $27.46 million in revenue each year. The medical research company earns $-17.81 million in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 107 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

Where are Biocept's headquarters?

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.